Skip to main content

Prevonco is currently available in France only.

CE marked · Available in France ¹

A blood test that helps detect 16 cancer types.

Free pre-registration with no commitment, with the early bird price reserved for the first 50 people when registration opens on 1 December 2026.

Free pre-registration Early bird: −100 € for the first 50 registrations
See the process

A simple blood test · No prescription needed

16
types of cancer detectable¹
+900
partner laboratories in France
10+ years
of French research on hPG80
30 min
with a functional medicine doctor committed to prevention
30 days
to receive your results
The burden of cancer

Despite progress, the burden of cancer continues to grow.

433 000

new cancer cases estimated in France in 2023, the latest national estimate: nearly 1,200 a day, a number that has doubled since 1990.²

1 in 5

Worldwide, around one in five people develops cancer during their lifetime³.

Why does it matter?

The earlier we know, the more we can do.

Early cancer detection starts with staying alert. A blood test with Prevonco gives you and your doctor a head start, well before symptoms appear.

A couple in their fifties cooking together in a bright kitchen with natural daylight

Silent for years

Most cancers develop without symptoms. By the time signs appear, the disease is often already advanced.

A gap in screening

Only 3 cancers have organised screening programmes in France.⁴⁵⁶ Breast, colorectal and cervical cancer. Lung cancer screening is in a pilot phase.⁷

5-YEAR SURVIVAL RATE⁸
FOUND AT A LATER STAGEFOUND EARLY
Kidney cancer
20 %
94 %
Colon cancer
17 %
91 %
Lung cancer
11 %
66 %

Despite organised screening,

1 in 3

colon cancers in France is found at an advanced stage, when treatment options become more limited.⁹

Prevonco.fr, an aid to the early detection of 16 cancer types, with a simple blood test and no prescription needed.¹

The cancers covered

The 16 cancers

Learn more
  • Organized cancer screening
  • Pilot program
  • No organized cancer screening
Your support

The process

  1. 01

    Order online

    Pay securely on our website. You will immediately receive a unique code with instructions for finding your nearest laboratory.

  2. 02

    Choose your doctor

    Choose a doctor from our panel and complete a health questionnaire. Our doctors practise functional medicine and have expertise in preventive healthcare. This questionnaire helps them tailor their approach and the interpretation of your results.

  3. 03

    Visit a laboratory for a blood test

    Show your code at one of the 900+ partner laboratories in France. Most do not require an appointment.

    A relaxed female patient welcomed by a female healthcare professional in a bright, modern medical laboratory
  4. 04

    Schedule your appointment

    After your blood test, book an appointment with the doctor you selected.

  5. 05

    Preparing for your consultation

    Your doctor receives your results and the information you provided in the health questionnaire to help prepare for your consultation.

  6. 06

    Consultation and results

    Join your video consultation. It lasts 30 minutes and is included in the service. Your doctor explains your results, interprets them in light of your circumstances, answers your questions and discusses next steps.

    • If your results are reassuring: your doctor helps you explore any health concerns and refine your prevention plan.
    • If your results need closer attention: your doctor may recommend further tests or refer you to a specialist.
Your result

Your result in 3 ranges

Your hPG80 level is expressed in picomoles per litre (pmol/L). Your doctor interprets it using three ranges.

  1. 3,3
    Low level · below 3.3

    Weak signal. No specific action needed if you have no symptoms.

  2. 10,9
    Intermediate level · 3.3 to 10.9

    Needs to be checked again. Your doctor considers your circumstances and may suggest other tests, followed by another hPG80 measurement.

  3. High level · above 10.9

    Further tests, guided by clinical findings, often including imaging.

Limitations of this test

The DxPG80 test is an aid to early cancer detection:

  • It does not locate cancer: an elevated level calls for further tests prescribed by a doctor.
  • False positives and false negatives can occur: no test is perfect.
Learn more: what can raise levels without cancer →

This test complements organised screening; it does not replace it.

  • Breast : A mammogram every 2 years, from age 50 to 74.⁴ Learn more
  • Colon and rectum : A home test every 2 years, from age 50 to 74.⁵ Learn more
  • Cervix : A cervical smear or HPV test, from age 25 to 65.⁶ Learn more
  • Lung : IMPULSION pilot programme for smokers and former smokers aged 50 to 74.⁷ Explore this programme

Prevonco is currently available in France only.

Pre-registration

Reserve your early bird price

Free pre-registration
289 €389 €−100 € · first 50 people to pre-register

Pre-registration is free: it reserves the early bird price of 289 € instead of 389 € (−100 €), available to the first 50 people to pre-register, when registration opens on 1 December 2026. No commitment.

Studies

What the studies say

  • 24 people with no symptoms: four cancer care journeys followed.¹⁰

    Intermediate or high levels: lung, colon and prostate.

    Read →
  • Lung cancer: a high hPG80 level guides further examinations, with no recurrence after 4 years.¹⁰

    High level in February 2020, surgery in July 2020: no recurrence at follow-up four years later.

    Read →
  • Biodena Care

    Who is behind this test?¹

    More than 10 years of French research.

    Read →
  • More than 4,000 patients studied.¹

    26 studies and 1,199 healthy people.

    Read →
  • 16 types of cancer, across all stages.¹

    High levels in 16 solid cancers.

    Read →
  • hPG80: a protein measured in the blood.¹

    Understand its role and the test's three interpretation ranges.

    Read →
  • After quitting smoking, levels may fall as early as the following month.¹

    What the study says about smoking and hPG80.

    Read →
View all studies →
Questions

Answers before you pre-register.

Do I really need a prescription?

No prescription needed. When you order through us, you receive a code giving you access to the test at any partner laboratory in France. A qualified doctor reviews your results with you to provide medical follow-up.

Which cancers can this test help detect?

Elevated levels of the hPG80 protein have been observed in 16 types of cancer, including lung, pancreatic, liver and colorectal cancers, with elevated levels observed from stage 1. For breast cancer, mammography through organised screening remains the standard.

What if my level is high?

An elevated level alone does not mean you have cancer. If your level is high, further tests prescribed by a doctor can help investigate the cause. An intermediate level may not be related to cancer: other blood tests may be suggested.

What if my level is low?

A low level is reassuring, but it does not rule out every cancer. Your 30-minute consultation with a functional medicine doctor is included whatever your result: they review it with you, help you explore any other health concerns and work with you on a prevention plan. Keep up with organised screening and see your doctor if a symptom appears.

How long will it take to get my results?

Laboratory analysis takes 30 days. A functional medicine doctor will explain your full results during a 30-minute consultation included in your service. You choose the date and time that suit you for this appointment.

Another question? Email us at contact@prevonco.fr.

Detect early signs of a cancer developing silently.

In 30 days, a clear answer, explained by a doctor.

Free pre-registration

−100 € for the first 50 people to pre-register

Breast cancer

Organized cancer screening

61,214 new cases in France in 2023

Breast cancer develops when cells in the mammary gland multiply abnormally.

5-year survival

FOUND AT A LATER STAGEFOUND EARLY
Localized
33,8 %
> 99 %

In France, 5-year net survival: 88 %.

Some possible signs

  • A lump in the breast or under the arm
  • Changes to the skin or nipple

These signs can have other causes. Unsure? Talk to your doctor.

Read the full guide →

Prostate cancer

No organized cancer screening

59 885 new cases in France (latest national estimate, 2018)

The prostate is a male gland located below the bladder.

5-year survival

FOUND AT A LATER STAGEFOUND EARLY
Localized
40,1 %
> 99 %

In France, 5-year net survival: 93 %.

Some possible signs

  • Urinary problems
  • Blood in the urine or semen

These signs can have other causes. Unsure? Talk to your doctor.

Read the full guide →

Lung cancer

Pilot program

52,777 new cases in France in 2023

Most lung cancers start in the cells lining the bronchi.

5-year survival

FOUND AT A LATER STAGEFOUND EARLY
Localized
10,5 %
65,5 %

At the localized stage, survival is about 6 times higher than at the metastatic stage.

Some possible signs

  • A cough that changes or persists
  • Coughing up blood
  • Shortness of breath

These signs can have other causes. Unsure? Talk to your doctor.

Read the full guide →

Colorectal cancer

Organized cancer screening

47,582 new cases in France in 2023

Colorectal cancer affects the colon or rectum.

5-year survival

FOUND AT A LATER STAGEFOUND EARLY
Localized
16,9 %
91,3 %

In France, 5-year net survival: 62 % in men, 65 % in women.

Some possible signs

  • Blood in the stool
  • Recent constipation or persistent diarrhea
  • Abdominal pain

These signs can have other causes. Unsure? Talk to your doctor.

Read the full guide →

Liver cancer

No organized cancer screening

11,658 new cases in France in 2023

Hepatocellular carcinoma arises from hepatocytes, the main cells of the liver.

5-year survival

FOUND AT A LATER STAGEFOUND EARLY
Localized
3,6 %
37,4 %

In France, 5-year net survival reaches about 50 % in people eligible for surgery or local destruction.

Some possible signs

  • Persistent severe fatigue
  • Loss of appetite, nausea
  • Pain on the right side, under the ribs

These signs can have other causes. Unsure? Talk to your doctor.

Read the full guide →

Ovarian cancer

No organized cancer screening

5 348 new cases of ovarian cancer in France in 2023

The main form of ovarian cancer (high-grade serous) most often starts in the fallopian tube.

5-year survival

FOUND AT A LATER STAGEFOUND EARLY
Localized
31,5 %
91,9 %

In France, 5-year net survival: 43 %.

Some possible signs

  • Bloating, feeling full quickly
  • Pain or heaviness in the lower abdomen
  • A frequent need to urinate

These signs can have other causes. Unsure? Talk to your doctor.

Read the full guide →

Uterine cancer (cervix and endometrium)

Organized cancer screening (cervix)

Endometrium (body of the uterus): 8 432 cases · cervix: 3 159 cases (France, 2023)

Uterine cancer covers two cancers.

5-year survival

FOUND AT A LATER STAGEFOUND EARLY
Localized endometrial cancer
94,9 %
Localized cervical cancer
91,8 %

In France, 5-year net survival: endometrium 74 %, cervix 63 %.

Some possible signs

  • Lower back or lower abdominal pain
  • Swollen legs
  • Urinary or digestive problems

These signs can have other causes. Unsure? Talk to your doctor.

Read the full guide →

Kidney cancer

No organized cancer screening

17,141 new cases in France in 2023

This is mainly renal cell carcinoma, which arises from cells in the kidney tubules.

5-year survival

FOUND AT A LATER STAGEFOUND EARLY
Localized
20,3 %
93,6 %

In France, 5-year net survival: 70 %.

Some possible signs

  • Blood in the urine
  • Pain in the side
  • A lump in the lower back

These signs can have other causes. Unsure? Talk to your doctor.

Read the full guide →

Esophageal cancer

No organized cancer screening

5 499 new cases of esophageal cancer in France in 2023

Two main forms: squamous cell carcinoma (upper esophagus) and adenocarcinoma (lower esophagus, near the stomach).

5-year survival

FOUND AT A LATER STAGEFOUND EARLY
Localized
5,3 %
48,6 %

In France, 5-year net survival: 16 to 20 %.

Some possible signs

  • Increasing difficulty swallowing, initially with large pieces of food
  • Weight loss
  • Chest pain

These signs can have other causes. Unsure? Talk to your doctor.

Read the full guide →

Stomach cancer

No organized cancer screening

6 515 new cases of stomach cancer in France in 2023

These are mainly adenocarcinomas, arising from glandular cells in the stomach wall.

5-year survival

FOUND AT A LATER STAGEFOUND EARLY
Localized
8,1 %
78,1 %

In France, 5-year net survival: 30 %.

Some possible signs

  • Upper abdominal pain
  • Nausea, repeated vomiting
  • Weight loss, fatigue

These signs can have other causes. Unsure? Talk to your doctor.

Read the full guide →

Cutaneous melanoma (skin melanoma)

No organized cancer screening

17 922 new cases of skin melanoma in France in 2023

Melanoma is a cancer of melanocytes, the cells that produce skin pigment.

5-year survival

FOUND AT A LATER STAGEFOUND EARLY
Localized
34 %
> 99 %

In France, 5-year net survival: 91 to 94 %.

Some possible signs

  • An enlarging lymph node near the area
  • Small lumps under the skin

These signs can have other causes. Unsure? Talk to your doctor.

Read the full guide →

Uveal melanoma (eye melanoma)

No organized cancer screening

500 to 600 new cases per year in France

Uveal melanoma is a cancer of melanocytes, the pigment-producing cells, that develops in the eye: it is the main eye cancer in adults.

5-year survival

FOUND AT A LATER STAGEFOUND EARLY
Localized
88 %

5-year relative survival in the United States. In France, 5-year net survival: 74 %.

Some possible signs

  • Blurred vision
  • A spot in the field of vision
  • Flashes of light

These signs can have other causes. Unsure? Talk to your doctor.

Read the full guide →

Neuroendocrine tumors

No organized cancer screening

Rare tumors: less than 1% of digestive cancers in France

Neuroendocrine tumors arise from hormone-producing cells found throughout the body.

Median survival by stage

Localized> 30 years
Distant12 months

Median survival (not 5-year survival), United States, 64 971 patients. No French figure available.

Some possible signs

  • Digestive problems, abdominal pain
  • Blood in the stool (rectum)

These signs can have other causes. Unsure? Talk to your doctor.

Read the full guide →

Pancreatic cancer

No organized cancer screening

15,991 new cases in France in 2023

In more than 9 in 10 cases, this is an adenocarcinoma, arising from the cells lining the ducts of the pancreas, the gland that produces digestive juices.

5-year survival

FOUND AT A LATER STAGEFOUND EARLY
Localized
3,4 %
43,6 %

At the localized stage, survival is about 13 times higher than at the metastatic stage. In France, 5-year net survival: 11 %.

Some possible signs

  • Loss of weight and appetite, fatigue
  • Digestive problems
  • New-onset diabetes

These signs can have other causes. Unsure? Talk to your doctor.

Read the full guide →

Glioblastoma

No organized cancer screening

3 481 new cases in France in 2018 (estimate, histologically confirmed glioblastomas)

Glioblastoma is a tumor that starts in the brain, arising from astrocytes, the supporting cells of the nervous system.

5-year survival

France (diagnoses 2010–2015)7 %

France: age-standardized 5-year net survival; United States: 5-year survival. In France, 1-year net survival improved by 21 percentage points between 1990 and 2015. To date, no study has shown that earlier detection improves survival: research continues.

Some possible signs

  • Unusual headaches, especially in the morning, with nausea or vomiting
  • A seizure
  • Depending on the area: problems with speech, vision or memory, weakness on one side of the body

These signs can have other causes. Unsure? Talk to your doctor.

Read the full guide →

Head and neck cancers (ENT)

No organized cancer screening

13 882 cancers of the lip, mouth and pharynx in France in 2023

These cancers arise from the mucous membrane lining the mouth, pharynx (the throat, including the tonsils and base of the tongue) and larynx (the vocal cords).

5-year survival

FOUND AT A LATER STAGEFOUND EARLY
Localized
36,0 %
88,7 %

In France, 5-year net survival: lip-mouth-pharynx 41 % in men and 56 % in women; larynx 59 %.

Some possible signs

  • A hoarse voice
  • A wound or mouth ulcer that does not heal
  • A sore throat, difficulty swallowing

These signs can have other causes. Unsure? Talk to your doctor.

Read the full guide →